Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Public ClinicalTrials.gov record NCT05756569. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Study identification
- NCT ID
- NCT05756569
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Emory University
- Other
- Enrollment
- 25 participants
Conditions and interventions
Conditions
- Bladder Adenocarcinoma
- Bladder Squamous Cell Carcinoma
- Locally Advanced Bladder Carcinoma
- Malignant Renal Pelvis Neoplasm
- Malignant Ureter Neoplasm
- Malignant Urethral Neoplasm
- Metastatic Bladder Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Unresectable Bladder Carcinoma
- Urachal Adenocarcinoma
Interventions
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Enfortumab Vedotin Drug
- Magnetic Resonance Imaging Procedure
- Pembrolizumab Biological
- Questionnaire Administration Other
Procedure · Drug · Biological + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2023
- Primary completion
- Dec 15, 2026
- Completion
- Dec 15, 2027
- Last update posted
- Jul 27, 2025
2023 – 2027
United States locations
- U.S. sites
- 4
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Grady Health System | Atlanta | Georgia | 30303 | Recruiting |
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | Recruiting |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 | Recruiting |
| Emory Saint Joseph's Hospital | Atlanta | Georgia | 30342 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05756569, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05756569 live on ClinicalTrials.gov.